Newbury Pharmaceuticals AB (NEWBRY) — Net Asset Quality Index
Newbury Pharmaceuticals AB (NEWBRY) has a Net Asset Quality Index of 40.5% as of February 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of Skr77.26 Million minus total liabilities of Skr45.96 Million yields net assets of Skr31.30 Million. A higher index indicates a stronger, lower-leverage balance sheet. Also explore Newbury Pharmaceuticals AB balance sheet assets for the complete picture of this company's asset base.
Quality Index
Net Assets
Total Assets
Total Liabilities
Newbury Pharmaceuticals AB Net Asset Quality Index Over Time (2021–2024)
This chart shows how Newbury Pharmaceuticals AB's Net Asset Quality Index has evolved across 4 annual periods from 2021 to 2024. As of February 2026, the index stands at 40.5%, representing net assets of Skr31.30 Million against total assets of Skr77.26 Million SEK. See NEWBRY working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Newbury Pharmaceuticals AB (2021–2024)
The table below presents the year-by-year Net Asset Quality Index for Newbury Pharmaceuticals AB from 2021 to 2024, covering 4 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Newbury Pharmaceuticals AB stock valuation.
| Year | Quality Index | Net Assets (SEK) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 57.1% | Skr51.92 Million | Skr90.87 Million | Skr38.95 Million | ▼ -10.6 pp |
| 2023 | 67.7% | Skr49.38 Million | Skr72.92 Million | Skr23.54 Million | ▼ -11.4 pp |
| 2022 | 79.1% | Skr68.77 Million | Skr86.91 Million | Skr18.14 Million | ▼ -10.7 pp |
| 2021 | 89.9% | Skr38.47 Million | Skr42.81 Million | Skr4.34 Million | — |